Company:  I-MAB (IMAB)
Form Type:  F-1/A
Filing Date:  1/14/2020 
CIK:  0001778016 
Address:  SUITE 802, WEST TOWER, OMNLVISION
88 SHANGKE ROAD, PUDONG DISTRICT
 
City, State, Zip:  SHANGHAI,  201210 
Telephone:  862160578000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$11.99  
Change: 
-0.15 (-1.24%)  
Trade Time: 
Feb 21  
Market Cap: 
$1.57B
Trade IMAB now with 

© 2020  
Description of Business
We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. We were founded to capture the opportunities presented by the confluence of two major developments--the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, fit-for-purpose technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China's biologics regulatory framework and our direct access to extensive pre-clinical and clinical trial resources in China.
Register and access this filing in:     
  FORM F-1/A
    CALCULATION OF REGISTRATION FEE
    EXPLANATORY NOTE
    PART II
      Item 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
      Item 7. RECENT SALES OF UNREGISTERED SECURITIES.
      Item 8. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
      Item 9. UNDERTAKINGS.
    EXHIBIT INDEX
    SIGNATURES
  EXHIBIT 1.1
    CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES ...
    Directors, Executive Officers and Others Signing Lock-up ...